Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progressionopen access
- Authors
- Oh, Sumin; Baek, Yang-Hyun; Jung, Sungju; Yoon, Sumin; Kang, Byeonggeun; Han, Su-Hyang; Park, Gaeul; Ko, Je Yeong; Han, Sang-Young; Jeong, Jin-Sook; Cho, Jin-Han; Roh, Young-Hoon; Lee, Sung-Wook; Choi, Gi-Bok; Lee, Yong Sun; Kim, Won; Seong, Rho Hyun; Park, Jong Hoon; Lee, Yeon-Su; Yoo, Kyung Hyun
- Issue Date
- Apr-2024
- Publisher
- 대한간학회
- Keywords
- Biomarker; Machine learning; MASLD; Multi-omics; Signature gene set
- Citation
- Clinical and Molecular Hepatology, v.30, no.2, pp 247 - 262
- Pages
- 16
- Journal Title
- Clinical and Molecular Hepatology
- Volume
- 30
- Number
- 2
- Start Page
- 247
- End Page
- 262
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/160319
- DOI
- 10.3350/cmh.2023.0449
- ISSN
- 2287-2728
2287-285X
- Abstract
- Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis and liver cancer, steatosis and MASH must be distinguished during patient treatment. Here, we investigate the genomes, epigenomes, and transcriptomes of MASLD patients to identify signature gene set for more accurate tracking of MASLD progression. Methods: Biopsy-tissue and blood samples from patients with 134 MASLD, comprising 60 steatosis and 74 MASH patients were performed omics analysis. SVM learning algorithm were used to calculate most predictive features. Linear regression was applied to find signature gene set that distinguish the stage of MASLD and to validate their application into independent cohort of MASLD. Results: After performing WGS, WES, WGBS, and total RNA-seq on 134 biopsy samples from confirmed MASLD patients, we provided 1,955 MASLD-associated features, out of 3,176 somatic variant callings, 58 DMRs, and 1,393 DEGs that track MASLD progression. Then, we used a SVM learning algorithm to analyze the data and select the most predictive features. Using linear regression, we identified a signature gene set capable of differentiating the various stages of MASLD and verified it in different independent cohorts of MASLD and a liver cancer cohort. Conclusions: We identified a signature gene set (i.e., CAPG, HYAL3, WIPI1, TREM2, SPP1, and RNASE6) with strong potential as a panel of diagnostic genes of MASLD-associated disease. © 2024 by Korean Association for the Study of the Liver.
- Files in This Item
-
Go to Link
- Appears in
Collections - 이과대학 > 생명시스템학부 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/160319)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.